From CRISPR screens to breakthrough: Bert defends PhD

Time to celebrate! Our dear colleague and friend Bert Kwanten successfully defended his PhD. In his thesis, he used CRISPR−Cas9 screening to identify genes that influence the response to the cancer drug selinexor, which targets XPO1. The results of these screens laid the foundation for uncovering a novel allosteric mechanism by which selinexor mediates targeted […]